Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: A 6-year follow-up

Annals of Hematology

Volumn 88, Issue 1, 2009, Pages 37-41

  Qin, Ya Zhen ^a   Jiang, Bin ^a   Jiang, Qian ^a   Jiang, Hao ^a   Li, Jin Lan ^a   Zhang, Yan ^a   Zhu, Hong Hu ^a   Li, Ling Di ^a   Chen, Shan Shan ^a   Liu, Yan Rong ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Chronic myeloid leukemia; Cytogenetic response; Event free survival; Imatinib; Molecular response; Real time quantitative RT PCR

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MESSENGER RNA;

ADULT; AGED; ARTICLE; BLAST CELL CRISIS; BONE MARROW EXAMINATION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; PIPERAZINES; PYRIMIDINES; RECURRENCE;

EID: 57049180944     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0548-y     Document Type: Article

References (20)

1. Rowley JD (1973) A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290-293 doi: 10.1038/243290a0
2. Shtivelman E, Lifshitz B, Gale RP, Canaani E (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315:550-554 doi: 10.1038/315550a0
3. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM (2007) Current and emerging treatment options in chronic myeloid leukemia. Cancer 109:2171-2181 doi: 10.1002/cncr.22661
4. Mughal TI, Yong A, Szydlo RM, Dazzi F, Olavarria E, van Rhee F et al (2001) Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol 115:569-574 doi: 10.1046/ j.1365-2141.2001.03155.x
5. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB et al (2003) Complete cytogenetic and molecular responses to interferon alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97:1033-1041 doi: 10.1002/ cncr.11223
6. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417 doi: 10.1056/ NEJMoa062867
7. Qin YZ, Liu YR, Zhu HH, Li JL, Ruan GR, Zhang Y et al (2008) Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response. Int J Lab Hematol 30:317-323
8. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432 doi: 10.1056/NEJMoa030513
9. Paschka P, Muller MC, Merx K, Kreil S, Schoch CB, Lahaye T et al (2003) Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 17:1687-1694 doi: 10.1038/ sj.leu.2403033
10. Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J et al (2005) Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: Patterns of residual leukemia and prognostic factors for cytogenetic relapse. Leukemia 19:507-512
11. Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N et al (2008) Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: The GIMEMA Working Party on CML. J Clin Oncol 26:106-111 doi: 10.1200/JCO.2007.13.2373
12. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004 doi: 10.1056/NEJMoa022457
13. Kantarjian H, Cortes J, O'Brien S, Luthra R, Giles F, Verstovsek S et al (2004) Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferonalpha. Blood 104:1979-1988 doi: 10.1182/blood-2004-02-0711
14. Hughes T, Branford S (2006) Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 20:29-41 doi: 10.1016/j.blre.2005.01.008
15. Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B et al (2004) Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 103:2284-2290 doi: 10.1182/blood-2003-07-2575
16. Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M et al (2006) Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 12:3037-3042 doi: 10.1158/1078-0432.CCR-05-2574
17. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J et al (2008) Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon- treatment. Blood 111:1039-1043 doi: 10.1182/blood-2007-07-103523
18. Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D et al (2006) Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol 24:454-459 doi: 10.1200/JCO.2005.03.2011
19. Goldman J (2005) Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. Curr Opin Hematol 12:33-39 doi: 10.1097/01.moh.0000148551.93303.9e
20. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al (2006) Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820 doi: 10.1182/blood-2006-02-005686